insulin resistance, obesity
Conditions
Interventions
Patients will be randomised to either 7 days amoxicillin 500mg 3dd or 7 days vancomycin 500mg 3dd.
Sponsors
Academic Medical Center, Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male obese subjects with metabolic syndrome (BMI > 30kg/m2, FPG>5.6 mmol/l); 2. Age 20-65 yr; 3. No medication use.
Exclusion criteria
Exclusion criteria: 1. Patients with renal failure (kreatinine>135mmol/l); 2. Liver function problems (ASAT/ALAT>2x upper limit); 3. Hypersensitivity to penicillin, amoxicillin, other beta lactams or chinolones; 4. Patients with medication known to interfere with glucose metabolism or bile acid composition (sequestrants, chenodiole, ursochol); 5. Patients with infectious mononucleosis; 6. Asthmatic patients; 7. Antibiotic use last three months; 8. Disorders known to interfere with bile acid metabolism (intestine resection, liver/intestine disorders); 9. History of laparoscopic cholecystectomy; 10. Patients with idiopathic diarrhea.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is changes in faecal flora composition after 7 days as well as 2, 4 and 6 weeks after the antibiotics. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes in insulin resistance (assessed by hyperinsulinemic normoglycemic clamp at baseline and after 7 days); 2. Bile acid and lipidmetabolism (assessed by MMT at baseline and after 7 days); 3. Changes in systemic inflammatory markers and lipid profiles at baseline as well as 7 days, 2, 4 and 6 weeks after antibiotics. | — |
Contacts
Public ContactA. Vrieze
PO Box 22660
Outcome results
None listed